What is United Therapeutics Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
United Therapeutics's operating assets for the quarter that ended in Dec. 2023 was $4,173 Mil. United Therapeutics's operating liabilities for the quarter that ended in Dec. 2023 was $482 Mil. United Therapeutics's Total Assets for the quarter that ended in Sep. 2023 was $7,024 Mil. Therefore, United Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.53.
United Therapeutics Scaled Net Operating Assets Historical Data
The historical data trend for United Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics Scaled Net Operating Assets Chart
|
United Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
Get a 7-Day Free Trial
|
|
|
0.63 |
0.60 |
0.61 |
0.53 |
0.61 |
|
United Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.48 |
0.51 |
0.56 |
0.54 |
0.53 |
Competitive Comparison of United Therapeutics's Scaled Net Operating Assets
For the Biotechnology subindustry, United Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, United Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Scaled Net Operating Assets falls into.
United Therapeutics Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
United Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (4172.9 | - | 482.2) | / | 6044.5 |
| = | 0.61 |
where
United Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Dec. 2023 ) |
| = | (Operating Assets (Q: Dec. 2023 ) | - | Operating Liabilities (Q: Dec. 2023 )) | / | Total Assets (Q: Sep. 2023 ) |
| = | (4172.9 | - | 482.2) | / | 7023.6 |
| = | 0.53 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (United Therapeutics) Business Description
Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
| Paul A Mahon |
officer: EVP & General Counsel |
|
| Nilda Mesa |
director |
C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910 |
| Christopher Causey |
director |
|
| Martine A Rothblatt |
director, officer: Chief Executive Officer |
|
| Louis W Sullivan |
director |
|
| Judy D. Olian |
director |
2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067 |
| Michael Benkowitz |
officer: President and COO |
C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910 |
| Christopher Patusky |
director |
|
| Raymond Dwek |
director |
|
| Linda Maxwell |
director |
1040 SPRING STREET, SILVER SPRING NC 27709 |
| Tommy G Thompson |
director |
7711 CARONDELET, ST. LOUIS MO 63105 |
| Katherine J Klein |
director |
STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104 |
| Richard Giltner |
director |
C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009 |
| Roger Jeffs |
director, officer: President and COO |
|
| David Zaccardelli |
officer: EVP & Chief Operating Officer |
300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069 |
United Therapeutics (United Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UTHR has been successfully added to your